18:44 , Nov 4, 2016 |  BioCentury  |  Emerging Company Profile

Exploiting alpha-GAL

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases. The newco’s Alphaject therapies are...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

Centauri Therapeutics completes venture financing

Centauri Therapeutics Ltd. , Kent, U.K.   Business: Infectious   Date completed: 2016-01-18   Type: Venture financing   Raised: Not disclosed   Investors: Animatrix Capital; private investors   Note: Centauri raised an undisclosed amount in...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Alpha-gal glycolipids: Phase I data

A Phase I trial in 9 patients with unresectable metastatic melanoma with >=1 resectable cutaneous, subcutaneous or palpable lymph node metastasis showed that 2 intratumoral injections of alpha-gal glycolipids given 4 weeks apart were well...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Agalimmune cancer news

Loxbridge Research LLP and Animatrix Capital LLP founded newco Agalimmune to develop immunotherapies to treat cancer, with a focus on solid tumors. Agalimmune has rights to Alphaject technology from the University of Massachusetts Medical Clinic....